A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis (NCT07003425)
A Long-term Extension Study to Evaluate the Safety and Efficacy of APG777 in Patients With Atopic Dermatitis Previously Treated With APG777
🩺 Plain-English Summary (8th-Grade Level)
This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948). The LTE study will consist of 3 periods: 1) Screening Visit will coincide with the last visit of the Maintenance Period in the Parent Study 2) Extended Treatment Period 3) Post-treatment Follow-up Period. This study will be conducted in participants with atopic dermatitis (AD) who completed the Treatment Period in a prior APG777 study and who, in the opinion of the Investigator, would benefit from long-term treatment with APG777.
Who can join: Review the eligibility criteria below.
Location: Investigational Site — Fountain Valley, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (68 Sites)
Showing the first 25 of 68 sites.
- Investigational Site — Fountain Valley, California
- Investigational Site — Los Angeles, California
- Investigational Site — Coral Gables, Florida
- Investigational Site — Jacksonville, Florida
- Investigational Site — Margate, Florida
- Investigational Site — Douglasville, Georgia
- Investigational Site — Skokie, Illinois
- Investigational Site — Bowling Green, Kentucky
- Investigational Site — Detroit, Michigan
- Investigational Site — Troy, Michigan
- Investigational Site — New York, New York
- Investigational Site — Wilmington, North Carolina
- Investigational Site — Boardman, Ohio
- Investigational Site — Mason, Ohio
- Investigational Site — Portland, Oregon
- Investigational Site — Pittsburgh, Pennsylvania
- Investigational Site — Charleston, South Carolina
- Investigational Site — Nashville, Tennessee
- Investigational Site — Dallas, Texas
- Investigational Site — Frisco, Texas
- Investigational Site — San Antonio, Texas
- Investigational Site — Mill Creek, Washington
- Investigational Site — Calgary, Alberta
- Investigational Site — Calgary, Alberta
- Investigational Site — Edmonton, Alberta
📞 Contact the Study Coordinator
Phone: (781) 208-2408
Email: ClinicalTrials@apogeetherapeutics.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Atopic Dermatitis
- A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden — Birmingham, Alabama
- ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis — Phoenix, Arizona
- A Study of Barzolvolimab in Patients With Atopic Dermatitis — Birmingham, Alabama
- Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis — Chicago, Illinois
- A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis — Birmingham, Alabama
- A Study Evaluating APG777 in Atopic Dermatitis — Fountain Valley, California
Explore by condition: All Atopic Dermatitis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.